ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.18
-0.13%
US Tech 100
19,482.00
-0.49%
S&P 500
5,738.17
-0.13%
US Dollar vs CAD
1.35145
0.27%
Bitcoin
65,719.04
0.82%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Can Fite BioPharma Ltd (CANF)

  7. Can Fite BioPharma Ltd (CANF) News

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:CANF
DateTimeSourceHeadlineSymbolCompany
09/24/20246:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
09/24/20246:00AMGlobeNewswire Inc.Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary OsteoarthritisAMEX:CANFCan Fite BioPharma Ltd
09/16/20246:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
09/16/20246:00AMGlobeNewswire Inc.Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of HealthAMEX:CANFCan Fite BioPharma Ltd
09/08/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
09/06/20243:30PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:CANFCan Fite BioPharma Ltd
09/05/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
08/30/20243:18PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
08/30/20243:18PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersAMEX:CANFCan Fite BioPharma Ltd
08/30/20243:16PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementAMEX:CANFCan Fite BioPharma Ltd
08/30/20243:15PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CANFCan Fite BioPharma Ltd
08/29/20247:46AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
08/29/20247:15AMGlobeNewswire Inc.Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAMEX:CANFCan Fite BioPharma Ltd
08/12/20245:45AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
08/09/20245:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
08/08/20246:01PMGlobeNewswire Inc.Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross ProceedsAMEX:CANFCan Fite BioPharma Ltd
07/29/20246:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
07/29/20246:00AMGlobeNewswire Inc.Can-Fite Provides Namodenoson Patent UpdateAMEX:CANFCan Fite BioPharma Ltd
07/17/20246:00AMGlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8AMEX:CANFCan Fite BioPharma Ltd
07/11/20246:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
07/11/20246:00AMGlobeNewswire Inc.Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
07/01/20246:00AMGlobeNewswire Inc.Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with NamodenosonAMEX:CANFCan Fite BioPharma Ltd
06/28/20246:00AMBusiness WirePositive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner VetbiolixAMEX:CANFCan Fite BioPharma Ltd
06/24/20246:00AMBusiness WireCan-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the LiverAMEX:CANFCan Fite BioPharma Ltd
06/10/20246:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
06/10/20246:00AMBusiness WireCan-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa StudyAMEX:CANFCan Fite BioPharma Ltd
06/07/20243:15PMEdgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]AMEX:CANFCan Fite BioPharma Ltd
06/05/20246:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
06/05/20246:00AMBusiness WireCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 StudyAMEX:CANFCan Fite BioPharma Ltd
05/29/20246:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
 Showing the most relevant articles for your search:AMEX:CANF

Your Recent History

USOTC
JRONY
Jeronimo Martins SGPS (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved